Meclofenoxate 51-68-3
Meclofenoxate (Lucidril), also known as centrophenoxine, is a drug used to treat the symptoms of senile dementia and Alzheimer's Disease. It is a compound of two biochemicals: dimethylaminoethanol (DMAE) and parachlorophenoxyacetate (pCPA). DMAE is a natural substance, found especially in fish, and also produced in the human brain. pCPA is a synthetic compound that resembles a variety of plant hormones called auxins. Like DMAE, it is a precursor to the neurotransmitter acetylcholine and may increase levels of this chemical in the CNS. It also increases cellular membrane phospholipids which is considered by some to be an important antiaging effect. It has been clinically shown to improve memory, have a mentally stimulating effect, and improve general cognition. It is also used off-label as a nootropic, often combined with a racetam drug such as piracetam. A typical nootropic dose is 250-3,000 mg taken in 1 or more doses.
Side effects and contraindications
Centrophenoxine is generally considered safe. However possible side effects may include nausea or mild dizziness. People with severely high blood pressure or convulsive disorders such as epilepsy should avoid Centrophenoxine. Large doses may cause tight jaw clenching.
| Systematic (IUPAC) name: | 2-dimethylaminoethyl (4-chlorophenoxy)acetate |
|---|---|
| Meclofenoxate CAS number: | 51-68-3 |
| ATC code: | N06BX01 |
| PubChem: | 4039 |
| DrugBank: | |
| Formula: | C12H16N1O3 |
| Molecular mass: | 257.713 g/mol |
| Meclofenoxate Assay/Purity: | Typically NLT 98% |
